HAE treatment
If left untreated, attacks gradually worsen over a 24-hour period and typically subside within 3 to 5 days.1–3 Treatment for HAE should be individualised to your patient’s needs and lifestyle to help reduce the burden of disease by preventing or attenuating attacks.4
HAE can be managed with:
|
Use |
|
|---|---|
|
Acute therapy4 |
For the treatment of acute attacks of HAE |
|
Short-term prophylactic therapy4 |
For the prevention of HAE attacks in patients with planned exposure to a situation likely to trigger an attack, such as dentistry and invasive medical and surgical procedures |
|
Long-term prophylactic therapy4 |
To minimise the frequency and severity of recurrent attacks |
According to the 2014 UK Consensus Guidelines, some of the key management strategies for HAE include:5
- All disabling attacks, irrespective of location, are eligible for treatment as soon as they are clearly recognised5
- Every patient (including children) should be offered the option of home administration with appropriate monitoring, training and governance5
- Every patient should hold a safe quantity (minimum of one) of acute treatment doses at home, dependent on individual needs5
- All patients should have a treatment plan for acute and elective surgery, including dentistry5
- Regular prophylactic treatment may be appropriate for patients requiring treatment for two or more attacks per week5
Please note that current treatment guidelines are for patients with Type I and Type II HAE only; the pathogenesis of other forms of HAE is not well-characterised, and therefore, therapeutic options may not be similarly effective.
References:
- Longhurst H, et al. Lancet 2012;379(9814):474–81.
- HAE UK. Available from: https://www.haeuk.org/what-is-hae/ Accessed August 2021.
- Henao MP, et al. Ther Clin Risk Manag 2016;12:701–11.
- Maurer M, et al. Allergy 2018;73(8):1575–96.
- Longhurst HJ, et al. Clin Exp Immunol 2015;180(3):475–83.
